Novo Nordisk SG&A Expenses 2010-2024 | NVO
Novo Nordisk annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Novo Nordisk sg&a expenses for the quarter ending September 30, 2024 were $2.446B, a 19.01% increase year-over-year.
- Novo Nordisk sg&a expenses for the twelve months ending September 30, 2024 were $9.560B, a 14.54% increase year-over-year.
- Novo Nordisk annual sg&a expenses for 2023 were $8.944B, a 24.62% increase from 2022.
- Novo Nordisk annual sg&a expenses for 2022 were $7.177B, a 9.87% increase from 2021.
- Novo Nordisk annual sg&a expenses for 2021 were $6.532B, a 15.6% increase from 2020.
Novo Nordisk Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$8,944 |
| 2022 |
$7,177 |
| 2021 |
$6,532 |
| 2020 |
$5,651 |
| 2019 |
$5,371 |
| 2018 |
$5,094 |
| 2017 |
$4,880 |
| 2016 |
$4,806 |
| 2015 |
$4,787 |
| 2014 |
$4,771 |
| 2013 |
$4,789 |
| 2012 |
$4,295 |
| 2011 |
$4,066 |
| 2010 |
$3,674 |
| 2009 |
$3,470 |
Novo Nordisk Quarterly SG&A Expenses
(Millions of US $) |
| 2024-09-30 |
$2,446 |
| 2024-06-30 |
$2,322 |
| 2024-03-31 |
$2,099 |
| 2023-12-31 |
$2,694 |
| 2023-09-30 |
$2,055 |
| 2023-06-30 |
$2,252 |
| 2023-03-31 |
$1,943 |
| 2022-12-31 |
$2,097 |
| 2022-09-30 |
$1,706 |
| 2022-06-30 |
$1,692 |
| 2022-03-31 |
$1,682 |
| 2021-12-31 |
$1,991 |
| 2021-09-30 |
$1,609 |
| 2021-06-30 |
$1,444 |
| 2021-03-31 |
$1,489 |
| 2020-12-31 |
$1,737 |
| 2020-09-30 |
$1,441 |
| 2020-06-30 |
$1,215 |
| 2020-03-31 |
$1,258 |
| 2019-12-31 |
$1,598 |
| 2019-09-30 |
$1,307 |
| 2019-06-30 |
$1,270 |
| 2019-03-31 |
$1,196 |
| 2018-12-31 |
$1,357 |
| 2018-09-30 |
$1,257 |
| 2018-06-30 |
$1,271 |
| 2018-03-31 |
$1,208 |
| 2017-12-31 |
$1,481 |
| 2017-09-30 |
$1,168 |
| 2017-06-30 |
$1,127 |
| 2017-03-31 |
$1,104 |
| 2016-12-31 |
$1,317 |
| 2016-09-30 |
$1,181 |
| 2016-06-30 |
$1,176 |
| 2016-03-31 |
$1,131 |
| 2015-12-31 |
$1,352 |
| 2015-09-30 |
$1,178 |
| 2015-06-30 |
$1,195 |
| 2015-03-31 |
$1,061 |
| 2014-12-31 |
$1,316 |
| 2014-09-30 |
$1,205 |
| 2014-06-30 |
$1,168 |
| 2014-03-31 |
$1,082 |
| 2013-12-31 |
$1,375 |
| 2013-09-30 |
$1,128 |
| 2013-06-30 |
$1,165 |
| 2013-03-31 |
$1,121 |
| 2012-12-31 |
$1,250 |
| 2012-09-30 |
$1,020 |
| 2012-06-30 |
$1,034 |
| 2012-03-31 |
$992 |
| 2011-12-31 |
$1,082 |
| 2011-09-30 |
$1,047 |
| 2011-06-30 |
$1,044 |
| 2011-03-31 |
$893 |
| 2010-12-31 |
$1,397 |
| 2010-09-30 |
$530 |
| 2010-06-30 |
$874 |
| 2010-03-31 |
$873 |
| 2009-12-31 |
$1,064 |
| 2009-09-30 |
$800 |
| 2009-06-30 |
$814 |
| 2009-03-31 |
$792 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$460.555B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
